logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 2 of 2 Items
Showing 1 - 2 of 2 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Risk factors associated with default from multi- and extensively drug-resistant tuberculosis treatment, Uzbekistan: a retrospective cohort analysis

Lalor MK, Greig J, Allamuratova S, Althomsons S, Tigay Z,  et al.
2013-11-06 • PLOS One
2013-11-06 • PLOS One
BACKGROUND
The Médecins Sans Frontières project of Uzbekistan has provided multidrug-resistant tuberculosis treatment in the Karakalpakstan region since 2003. Rates of default from t...
Journal Article
|
Research

Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan

Kuhlin J, Smith C, Khaemraev A, Tigay Z, Parpieva N,  et al.
2018-05-01 • International Journal of Tuberculosis and Lung Disease
2018-05-01 • International Journal of Tuberculosis and Lung Disease
SETTING
The World Health Organization (WHO) recommends the inclusion of pyrazinamide (PZA) in treatment regimens for multidrug-resistant tuberculosis (MDR-TB) unless resistance has b...